Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients

References

• Chen CJ, Yang HI, Su J et al. REVEAL-HBV Study Group: risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295(1), 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J et al. Impact of chronically elevated HBV DNA viral load on risk of HCC occurrence: an update from the R.E.V.E.A.L-HBV Study. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23–26 March 2008. Hepatol. Int.2, A208–A209 (2008) (Abstract PE1015).
   Google Scholar
• Chen CF, Yang HI, Iloeje UH et al. Changes in serum HBV-DNA level using a trajectory model to predict the risk of HCC in chronic hepatitis B patients: the R.E.V.E.A.L-HBV Study. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23–26 March 2008. Hepatol. Int.2, A188 (2008) (Abstract FP135).
   Google Scholar
• Iloeje UH, Yang HI, Su J et al. HBV viral load less than 104 copies/ml is associated with significant risk of hepatocellular carcinoma in chronic hepatitis B patients: an update from the R.E.V.E.A.L -HBV study. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23–26 March 2008. Hepatol. Int.2, A187–A188 (2008) (Abstract FP133).
   Google Scholar
• AASLD Practice Guidelines. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology45(2), 507–539 (2007).
   PubMed Web of Science ®Google Scholar
• APASL Consensus Statement. Liaw YF, Leung N, Guan R et al. Asian–Pacific consensus update working party on chronic hepatitis B. Asian–Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int.25(3), 472–489 (2005).
   PubMed Web of Science ®Google Scholar
• US HBV Treatment Algorithm. Keeffe EB, Dieterich DT, Han SH et al.A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin. Gastroenterol. Hepatol.4(8), 936–962 (2006).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Yuan HJ, Wong DK et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut54(11), 1610–1614 (2005).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon a treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology34(1), 139–145 (2001).
   PubMed Web of Science ®Google Scholar
• Zhu Y, Yamamoto T et al. Kinetics of Hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J. Virol.75(1), 311–322 (2001).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med.341(17), 1256–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med.339(2), 61–68 (1998).
   PubMed Web of Science ®Google Scholar
• Schalm SW, Heathcote J, Cianciara J et al. Lamivudine and a interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut46(4), 562–568 (2000).
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol.19(11), 1276–1282 (2004).
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology125(6), 1714–1722 (2003).
   PubMed Web of Science ®Google Scholar
• Manns M, Jeffers L, Dalekos G et al. The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naïve and LAM‑experienced subjects treated for chronic hepatitis B (CHB). Presented at: the 43rd Annual Conference of the European Association for the Study of the Liver (EASL), Seoul, Korea, 23–26 March 2008. J. Hepatol.48(S1), s33 (2008) (Abstract 74).
   Google Scholar
• Heathcote J, George J, Gordon S et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 103). Presented at: the 43rd Annual Conference of the European Association for the Study of the Liver (EASL), Seoul, Korea, 23–26 March 2008. J. Hepatol.48(S1), s32 (2008) (Abstract 72).
   Web of Science ®Google Scholar
• Marcellin P, Jacobson I, Habersetzer F et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (Study 102). Presented at: the 43rd Annual Conference of the European Association for the Study of the Liver (EASL), Seoul, Korea, 23–26 March 2008. J. Hepatol.48(S1), s26 (2008) (Abstract 57).
   Web of Science ®Google Scholar
• Bisacchi GS, Chao ST, Bachard C et al. BMS-200475, a novel carbocyclic 2´-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro.Bioorg. Med. Chem. Lett.7(2), 127–132 (1997).
   Web of Science ®Google Scholar
• Domaoal RA, McMahon M, Thio CL et al. Pre-steady-state kinetic studies establish entecavir 5´-triphosphate as a substrate for HIV-1 reverse transcriptase. J. Biol. Chem.283(9), 5452–5459 (2008).
   PubMedGoogle Scholar
• Yamanaka G, Wilson T, Innaimo S et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Chemother.43(1), 190–193 (1999).
   PubMed Web of Science ®Google Scholar
• Innaimo SF, Seifer M, Bisacchi GS et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Chemother.41(7), 1444–1448 (1997).
   PubMed Web of Science ®Google Scholar
• Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother.42(12), 3200–3208 (1998).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother.51(3), 902–911 (2007).
   PubMed Web of Science ®Google Scholar
• Baldick CJ, Tenney DJ, Mazzucco CE et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology47(5), 1473–1482 (2008).
   PubMed Web of Science ®Google Scholar
• McMahon MA, Jilek BL, Brennan, TP et al. Drug entecavir – effects on HIV-1 replication and resistance. N. Engl. J. Med.356(25), 2614–2621 (2007)
   PubMed Web of Science ®Google Scholar
• Sasadeusz J, Audsley J, Mijch A et al. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients. AIDS22(8), 947–955 (2008).
   PubMed Web of Science ®Google Scholar
• Lin PF, Nowicka-Sans B, Terry B et al. entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge. Antimicrob. Agents. Chemother.52(5), 1759–1767 (2008).
   PubMedGoogle Scholar
• Colonno RJ, Genovesi EV, Medina I et al. Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. J. Infect. Dis.184(10), 1236–1245 (2001).
   PubMed Web of Science ®Google Scholar
• Marion PL, Salazar FH, Winters MA, Colonno RJ. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob. Agents Chemother.46(1), 82–88 (2002).
   PubMed Web of Science ®Google Scholar
• Genovesi EV, Lamb L, Medina I et al. Efficacy of the carbocyclic 2´-deoxyguanosine nucleoside BMS‑200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother.42(12), 3209–3217 (1998).
   PubMed Web of Science ®Google Scholar
• Foster WK, Miller DS, Marion PL et al. entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Antimicrob. Agents Chemother.47(8), 2624–2635 (2003).
   PubMed Web of Science ®Google Scholar
• de Man RA, Wolters LM, Nevens F et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology34(3), 578–582 (2001).
   PubMed Web of Science ®Google Scholar
• Lai CL, Rosmawati M, Lao J et al. entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology123(6), 1831–1838 (2002).
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, Hadziyannis SJ et al. BEHoLD Study Group. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology129(4), 1198–1209 (2005)
   PubMed Web of Science ®Google Scholar
• Chang TT, Gish RG, de Man R et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med.354(10), 1001–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Gish RG, Lok AS, Chang TT et al. entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology133(5), 1437–1444 (2007).
   PubMed Web of Science ®Google Scholar
• Chang TT, Chao YC, Yoon SK et al. Four-year treatment with entecavir results in high proportions of nucleoside-naive HBeAg-positive patients with undetectable HBV DNA: results from studies ETV-022 and -901. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23–26 March 2008. Hepatol. Int.2, A111–A112 (2008) (Abstract FP001).
   PubMedGoogle Scholar
• Lai CL, Shouval D, Lok AS et al. BEHoLD AI463027 study group. entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med.354(10), 1011–1020 (2006). Erratum in N. Engl. J. Med.354(17), 1863 (2006).
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Sollano J et al. AI463026 BEHoLD study group. entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology130(7), 2039–2049 (2006).
   PubMed Web of Science ®Google Scholar
• Sherman M, Yurdaydin C, Simsek H et al. entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology48, 99–108 (2008).
   PubMed Web of Science ®Google Scholar
• Leung N, Peng C-Y, Sollano J et al. entecavir results in higher HBV DNA reduction versus adefovir in chronically infected HBeAg+ antiviral-naive adults: 48-week results (E.A.R.L.Y. study). Presented at the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL). Seoul, Korea, 23–26 March 2008. Hepatol. Int.2, A113–A114 (2008) (Abstract FP007).
   Google Scholar
• Chang TT, Lai CL, Han S et al. Efficacy of entecavir in nucleoside-naïve patients with mildly elevated ALT. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23–26 March 2008. Hepatol. Int.2, A223–A224 (2008) (Abstract PE1070).
   Google Scholar
• Simsek H, Schiff E, Goodman Z et al. Efficacy of entecavir and lamivudine in chronic hepatitis b patients with advanced liver fibrosis/cirrhosis. Presented at: the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL), Seoul, Korea, 23–26 March 2008. J. Hepatol.46(S1), S197 (2008) (Abstract 518).
   Google Scholar
• Wong DK, Yuen MF, Ngai V et al. One-Year treatment of entecavir results in reduction in intrahepatic covalently closed circular DNA level. Presented at: the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA, USA, 11–15 November 2005. Hepatology42(4 Suppl. 1) A573 (2005) (Abstract 960).
   Google Scholar
• Colonno RJ, Rose R, Baldick CJ et al. entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology44(6), 1656–1665 (2006).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother.51(3), 902–911 (2007).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Pokomowski KA, Rose RE et al. entecavir at five years shows long-term maintenance of high genetic barrier to Hepatitis B virus resistance. Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23–26 March 2008. Hepatol. Int.2, A88–A89 (2008) (Abstract PL02).
   Google Scholar
• Yokosuka O, Kumada H, Toyota J et al. Three year assessment of entecavir (ETV) resistance in nucleoside-naive and lamivudine (LVD) refractory Japanese patients with chronic hepatitis B (CHB). Presented at: the 18th Annual Conference of the Asian Pacific Association for the Study of the Liver (APASL), Seoul, Korea, 23–26 March 2008. Hepatol. Int.2, A161 (2008) (Abstract FP067).
   Google Scholar
• Sherman M. Martin P, Lee WM et al. entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg+ chronic hepatitis B patients (ETV-026). Gastroenterology130(4 Suppl. 2), 765 (2006) (Abstract 478).
   Google Scholar
• Poordad F, Dietrich DT, Min AD et al. Continued virologic improvement through 96 weeks of entecavir treatment in HBeAg- chronic hepatitis B patients (STUDY ETV‑027). Gastroenterology130(4 Suppl. 2), 848 (2006) (Abstract T1851).
   Google Scholar
• Robinson DM, Scott LJ, Plosker GL. Entecavir: a review of its use in chronic hepatitis B. Drugs66(12), 1605–1622; discussion 1623–1624 (2006).
   PubMed Web of Science ®Google Scholar